1. Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging 
Jennifer Q. Zhang, BS, Craig M. Hooker, MPH, Malcolm V. Brock, MD, James Shin, BS, Sue Lee, BS, Remealle How, MD, Noreli Franco, PhD, Helen Prevas, BS, Alicia Hulbert, MD, Stephen C. Yang, MD 
The Annals of Thoracic Surgery 
Volume 93, Issue 2, Pages (February 2012)
DOI: /j.athoracsur
Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Kaplan-Meier curves of overall survival rates for 14 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 55 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by operation, with 5-year survival rates of 49.5% vs 53.8%, respectively.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Kaplan-Meier curves of recurrence-free survival rates for 10 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 50 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by an operation, with 5-year recurrence-free survival rates of 80% vs 63%, respectively. This analysis excluded 7 patients who were margin-positive and 2 patients with unknown margin status.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions